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Glycemia and Insulin Need Following FK 506 Rescue Therapy in Liver 
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L. Mieles. A.D. Gordon. D. Mintz. A.M. Toussaint. O. Imventarza. and T.E. Starzl 
DURING the last decade. newly acquired diabetes 
mellitus has been reponed to follow kidney trans-
plantation in 10% to 46% of the patientsKD·~ Although 
prednisone was thought to be a major factor in azathio-
prine regimens long before the advent of cyclosporine 
(CyA).1.4.6 the diabetogenic influence ofCyA has received 
much recent attention. OKPK~KT Diabetogenic effects also have 
been ascribed to FK 506. both in animalsH•9 and in 
humans. 10-13 In this study. the changes in glucose metab-
olism were recorded in 72 liver transplant recipients who 
were changed from Cy A to FK 506 therapy because of 
either uncontrolled rejection or toxicity of the conven-
tional immunosuppressive regimens. or for both reasons. 
MATERIALS AND METHODS 
The original case list included all of the first 81 liver recipients 
changed from eyA to FK S06. Nine of these were excluded from 
the analysis herein reported because of previous total pancreatec-
tomy (I I. a prolonged need for total insulin-containing parenteral 
infusions (I I. and multisystem failure with early death (7). Of the 
72 patients who were included. 63 were adults: 39 were men and 
24 women. The mean age of the adults were 44.S :!: 13.7 SO 
(range. 18 to 66). The nine children were 7.81 :!: 6.23 SO years old 
(range. 0.8 to 17.SI. 
The patients were changed from CyA to FK S06 between March 
I. 1989 and November IS. 1989: follow-ups continued until 
January IS. 1990. If the interval between livertransplantation and 
the institution of FK S06 therapy was less than 4 weeks. the 
patients were classified as having "early rescue" <Table I), These 
recipients tended to be very ill because of severe acute and/or 
beginning chronic liver rejection. which had not responded to 
additional steroids and OKTJ therapy. The "late rescue" group 
faced retransplantation because of chronic rejection or because 
the patients had serious CyA or steroid toxicity <Table I I. 
The records of all patients were reviewed for past or present 
evidence of insulin-dependent diabetes mellitus (lDOMI or non-
insulin-dependent diabetes mellitus (NIOOMI. In recipients who 
did not require insulin therapy. N 100M was diagnosed if three or 
more fasting blood sugars were found above 140 mgldL. The 
nonparametric sign test was used to evaluate the meaning of 
changes in the diabetic classification of the patients before and 
after treatment with FK S06. using a significance level of P < .05 
(SPSS. Statistical Software. Chicago. 1I1l. 
In addition. for 10 weeks before and 17 weeks after the drug 
switch. correlations were made between the level of blood glu-
cose. serum total bilirubin. alanine aminotransferase (ALT>. se-
rum creatinine. dosages of prednisone. CyA. and FK S06. Whole 
blood CyA levels were followed with TOx (Abbot Laboratories. 
Chicago, radioimmunoassay.14 FK S06 plasma levels were deter-
mined with the enzyme immunoassay technique of Tamura et alKl~ 
but these were obtained only sporadically during this early phase 
of our rescue trials. 
RESULTS 
Outcome of Rescue Therapy 
Rejection was present in 65 of the 72 (90%) patients (Table 
I). In seven patients (9.7%) CyA and/or steroid toxicity 
was the reason for the switch. The original diagnosis of 
acute rejection in one patient was later revised to primary 
nonfunction. The 74.4% success rate of the rescue therapy 
for the entire group in the present study (Table I) was 5% 
higher than previously reponed for the same group of 
patients because the nine exclusions from the present 
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Table 1. Indlcetlons and Outcome of Rescue Therapy In 72 Liver Allograft Recipients 
EartyR_ Late Rescue Total 
No. of No. of No. of No. of No. of No. of 
Indications Patients Success Patients Success Patients Success 
ChroniC rejection 2 1 31 22 33 23 
Acute rejection 10 10 14 11 24 21 
Acute and chronic rejection 0 0 2 2 2 2 
Chromc rejection and other 0 0 3 2 3 2 
Acute rejection and other 2 0 3 1 
CyA andlor steroid toXICity 6 5 6 5 
Primary nonfunction 0 0 
Total 14 12 (85.7"10) 58 42 (72.4%) 72 54(74.4%) 
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Fig 1. Liver and kidney function during the 10 weeks preceding 
and the 17 weeks following rescue therapy in 72 liver allograft 
recipients. 
study were included in the study of Fung et al. 13 Seven of 
these nine were recorded as failed rescues. 
During the 10 weeks preceding the drug switch. serum 
bilirubin and AL T slowly rose from week -10 to the time 
of the FK 506 switch. This reflected the deterioration that 
provided the reason for changing therapy. After the 
switch. these values declined to or toward normal (Fig I). 
The mean serum creatinine had begun a progressive rise 
before the FK 506 switch. This continued to increase for 10 
weeks after the drug change. before a tendency to decline 
was noticed. This reversible deterioration of renal function 
preceding and following the FK 506 switch was similar to 
that described earlier. 13.16 
Incidence of Diabetes Before and After Drug Switch 
Overall. there was a small but not statistically significant 
(sign test P > .12) increase from 32% to 37.5% of impaired 
glucose metabolism (Fig 2). Before the drug change. 49 
patients were classified as normal. II had NIOOM. and 12 
had 100M. Afterwards 45 were classified as normal. 13 
had NIOOM. and 14 had 100M. 
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Fig 2. Diabetic status before and after treatment with FK 506 .•. 
before FK 506: II. after FK 506 . 
Correlations in the Nondiabetic Subgroup 
In the 49 patients who were classified as normal before the 
switch to FK 506. the average fasting blood sugar slowly 
increased from 95 mgldL :t 3.86 SE on week -10 to III 
mgldL :t 7.32 SE on week - 2. and then to 131 :t 24.25 SE 
on week +6. After this. there was a steady decline to 93 
mgldL :t 4.96 SE by week + 17. During the pre-switch 
interval there were also major increases in the average 
prednisone doses and less dramatic rises in eyA blood 
levels. This pattern reflected attempts to control rejection 
as the day of the drug switch approached. After patients 
were switched to FK 506. prednisone treatment was 
decreased and after week +6 the average daily dose was 
5.37 mg :t 2.11 SE (Fig 3). Since the majority of patients 
require less FK 506 once rejection is controlled. the FK 
506 doses were also progressively reduced. 
Correlations in the NIDDM Subgroup 
With increased conventional immunosuppression. the av-
erage fasting blood sugars in these II patients rose from 
103.6 mgldL :t 12.24 SE to 187 :t 44.81 SE during the 10 
weeks preceding FK 506 therapy. These remained high 
thereafter (Fig 4). Insulin was given to six of these patients 
for several days before and/or after the drug change. and in 
one the need for insulin eventually became permanent. 
Correlations in the IDDM Subgroup 
The same pattern of increasing mean blood glucose levels 
was seen in association with increasing conventional im-
munosuppression leading to FK 506. Multiple adjustments 
of daily insulin made fUMher correlations impossible. 
DISCUSSION 
It is well known that whole organ recipients are susceptible 
to new onset diabetes in the postoperative period. When 
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Fig 3.. Immunosuppression and average fasting blood sugar. before and after the drug switch. in 49 nondiabetic patients. 
azathioprine and prednisone were used together in kidney 
recipients .. the incidence of diabetes seemed related to the 
quantities of steroids that were required for rejection 
control. 1.4.6 This same association was noted using 
CyA. 2 •3 but with growing realization that CyA is itself 
intrinsically diabetogenic.2.7.17-2u Cy A inhibits the release 
of insulin.I'J may cause permanent structural and func-
tional damage to animals .. 21 and also has been reported to 
increase peripheral insulin resistance_ 22 
There have been no previous studies of the incidence 
and features of diabetes mellitus after liver transplantation. 
Of the 72 liver recipients under Cy A-steroid therapy herein 
reported. 23 (32%) already had diabetes when they entered 
the study and 12 (17%) were being given insulin daily. This 
rate is comparable with that after kidney transplan-
tation. 1-5 In treating these patients. we attempted to define 
the effect. if any. a change from CyA to FK 506 would 
have on this preexisting complication. and to see if there 
would be new examples of diabetes. 
The analysis was complicated by the increased immu-
nosuppression {especially with prednisone) that was given 
prior to the switch in an effort to treat hepatic graft 
dysfunction. Presumably. this change contributed to the 
Increases in blood sugar and rises in serum creatinine that 
were noted before and after the institution of FK 506. 
Reversal of these undesirable changes required weeks or 
months after the switch. However. the basic diabetic 
profile changed only minimally. Most of the patients who 
did not have diabetes remained that way and patients who 
already had diabetes remained so. One patient who was 
insulin free before the switch required this treatment 
permanently afterwards. In the meanwhile. the central 
objectives of salvaging the liver grafts or ameliorating drug 
toxicity were met in three fourths of the patients. 
The mechanism of either CyA or FK 506 toxicity is not 
known. but a plausible hypothesis can be advanced from 
recent advances in enzyme chemistry. Cyclophilin. the 
ubiquitously distributed binding site of CyA is rich in 
peptidyl propyl isomerase (PPIase).23.24 an enzyme that 
facilitates protein folding and the catalysis of oligopeptide 
bonds. 25 The cytosolic binding site of FK 506 also contains 
PPlase. 26.27 Because both CyA and FK 506 cause strik-
ingly similar immunologic as well as metabolic alterations 
of mUltiple organ systems. it has been speculated that 
these chemically unrelated drugs act through PPlase 
inhibition. 2H.2'J If this were true. FK 506 also should be 
diabetogenic. and we have reported clinical evidence to 
support this_ 10-13 Studies of cultured rodent and human 
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Fig 4. Immunosuppression and average fasting blood sugar, before and after the drug switch, in the 11 NIDDM diabetics. 
islets have been confirmatory.:lO.:I' Although the experi-
mental studies have demonstrated a better therapeutic to 
toxic ratio for FK 506. the differences between the drugs 
were not fundamental. 
At a practical level. it is clear that double diabetogenic 
jeopardy is the price for using either CyA or FK 506 in 
combination with prednisone. The balance should be fa-
vorably altered if the use of steroids can be minimized as 
usually is possible with FK 506."- 13 In the study herein 
reponed. the diabetes problem was peripheral to the main 
purpose of salvaging rejecting liver grafts or ameliorating 
toxicity from immunosuppression regimens. 
Funher basic and clinical investigations of the diabeto-
genic effects of FK 506 will have implications beyond the 
field of transplantation. The potency and safety of this drug 
are great enough to envision its use as the sole therapy for 
a variety of T-cell mediated autoimmune disorders includ-
ing insulin-dependent diabetes. BB rat diabetes. which is 
analogous to type I human diabetes_ can be prevented 
completelv with nontoxic doses of fK 506- 1 '" the same 
way as previously demonstrated with CyA. 33 What re-
mains to be determined fully is the clinical liability of such 
therapy. An encouraging note is that the previously unat-
tainable objective of human pancreatic islet cell transplan-
tation has been achieved with FK 506 in several patients of 
whom one is insulin free more than 6 months later.:l4 
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